XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
- Author:
Xiao-Li ZHU
1
;
Xin-Chen SUN
;
Bao-An CHEN
;
Ning SUN
;
Hong-Yan CHENG
;
Fan LI
;
Hong-Ming ZHANG
;
Ji-Feng FENG
;
Shu-Kui QIN
;
Lu CHENG
;
Zu-Hong LU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carboplatin; administration & dosage; Carcinoma, Non-Small-Cell Lung; drug therapy; genetics; pathology; Cisplatin; administration & dosage; DNA-Binding Proteins; genetics; Female; Genotype; Humans; Lung Neoplasms; drug therapy; genetics; pathology; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prospective Studies
- From: Chinese Medical Journal 2010;123(23):3427-3432
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDPlatinum-based chemotherapeutics are the most common regimens for advanced non-small-cell lung cancer (NSCLC) patients, and genetic factors are thought to represent important determinants of drug efficacy. We prospectively assessed the status of the XPC Ala499Val and Lys939Gln gene polymorphisms and investigated whether these SNPs can predict the response to cisplatin/carboplatin-based regimens in advanced NSCLC patients in a Chinese population.
METHODSThe treatment outcomes of 96 advanced NSCLC patients who were treated with platinum-based chemotherapy were evaluated. The polymorphic status of xeroderma pigmentosum group C (XPC) gene was genotyped by the 3-D polyacrylamide gel-based DNA microarray method.
RESULTSThe distributions of XPC Lys939Gln genotypes differed significantly between the response group (complete + partial responses) and the non-response group (stable + progressive disease; P = 0.022). The heterozygous A/C genotype carriers had a poorer response rate than the wild A/A genotype carriers in stage III (OR, 0.074; 95%CI, 0.008 - 0.704; P = 0.023). The XPC Ala499Val polymorphisms were not associated with response to platinum-based chemotherapy.
CONCLUSIONPolymorphisms of the XPC gene, Lys939Gln, may be a predictive marker of treatment response for advanced NSCLC patients in stage III.
